Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Syvalahti, E' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 50 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Laakso, A; Bergman, J; Haaparanta, M; Vilkman, H; Solin, O; Syvalahti, E; Hietala, J
      Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia

      SCHIZOPHRENIA RESEARCH
    2. Laakso, MP; Tiihonen, J; Syvalahti, E; Vilkman, H; Laakso, A; Alakare, B; Rakkolainen, V; Salokangas, RKR; Koivisto, E; Hietala, J
      A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naive schizophrenia

      SCHIZOPHRENIA RESEARCH
    3. Hietala, J; Kuoppamaki, M; Majasuo, H; Palvimaki, EP; Laakso, A; Syvalahti, E
      Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist butnot antagonist binding to 5-HT2c receptors after chronic treatment

      PSYCHOPHARMACOLOGY
    4. Penttila, J; Syvalahti, E; Hinkka, S; Kuusela, T; Scheinin, H
      The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system - A randomised placebo-controlled study on healthy volunteers

      PSYCHOPHARMACOLOGY
    5. Hale, A; Azorin, JM; Kasper, S; Maier, W; Syvalahti, E; Van der Burght, M; Sloth-Nielsen, M; Wehnert, A
      Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    6. Hale, A; Azorin, JM; Kasper, S; Maier, W; Syvalahti, E; Van der Burght, M; Sloth-Nielsen, M; Wehnert, A
      Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    7. Lehtinen, V; Aaltonen, J; Koffert, T; Rakkolainen, V; Syvalahti, E
      Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?

      EUROPEAN PSYCHIATRY
    8. Taiminen, T; Salokangas, RKR; Saarijarvi, S; Syvalahti, E; Niemi, H; Ahola, V; Lehto, H
      Symptom dimensions, social network, and caregiver burden in chronic schizophrenia

      NORDIC JOURNAL OF PSYCHIATRY
    9. Rasanen, S; Pakaslahti, A; Syvalahti, E; Jones, PB; Isohanni, M
      Sex differences in schizophrenia: A review

      NORDIC JOURNAL OF PSYCHIATRY
    10. Vilkman, H; Kajander, J; Nagren, K; Oikonen, V; Syvalahti, E; Hietala, J
      Measurement of extrastriatal D-2-like receptor binding with [C-11]FLB 457 - a test-retest analysis

      EUROPEAN JOURNAL OF NUCLEAR MEDICINE
    11. Hallikainen, T; Lachman, H; Saito, T; Volavka, J; Kauhanen, J; Salonen, JT; Ryynanen, OP; Koulu, M; Karvonen, MK; Pohjalainen, T; Syvalahti, E; Hietala, J; Tiihonen, J
      Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior

      AMERICAN JOURNAL OF MEDICAL GENETICS
    12. Salokangas, RKR; Vilkman, H; Ilonen, T; Taiminen, T; Bergman, J; Haaparanta, M; Solin, O; Alanen, A; Syvalahti, E; Hietala, J
      High levels of dopamine activity in the basal ganglia of cigarette smokers

      AMERICAN JOURNAL OF PSYCHIATRY
    13. Laakso, A; Vilkman, H; Alakare, B; Haaparanta, M; Bergman, J; Solin, O; Peurasaari, J; Rakkolainen, V; Syvalahti, E; Hietala, J
      Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography

      AMERICAN JOURNAL OF PSYCHIATRY
    14. Hallikainen, T; Saito, T; Lachman, HM; Volavka, J; Pohjalainen, T; Ryynanen, OP; Kauhanen, J; Syvalahti, E; Hietala, J; Tiihonen, J
      Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior

      MOLECULAR PSYCHIATRY
    15. Tiihonen, J; Hallikainen, T; Lachman, H; Saito, T; Volavka, J; Kauhanen, J; Salonen, JT; Ryynanen, OP; Koulu, M; Karvonen, MK; Pohjalainen, T; Syvalahti, E; Hietala, J
      Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism

      MOLECULAR PSYCHIATRY
    16. Hietala, J; Syvalahti, E; Vilkman, H; Vuorio, K; Rakkolainen, V; Bergman, J; Haaparanta, M; Solin, O; Kuoppamaki, M; Eronen, E; Ruotsalainen, U; Salokangas, RKR
      Depressive symptoms and presynaptic dopamine function in neuroleptic-naiveschizophrenia

      SCHIZOPHRENIA RESEARCH
    17. Hietala, J; Nagren, K; Lehikoinen, P; Ruotsalainen, U; Syvalahti, E
      Measurement of striatal D-2 dopamine receptor density and affinity with [C-11]-raclopride in vivo: A test-retest analysis

      JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
    18. Kanerva, H; Vilkman, H; Nagren, K; Kilkku, O; Kuoppamaki, M; Syvalahti, E; Hietala, J
      Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration - a positron emission tomography study

      PSYCHOPHARMACOLOGY
    19. TIIHONEN J; VILKMAN H; RASANEN P; RYYNANEN OP; HAKKO H; BERGMAN J; HAMALAINEN T; LAAKSO A; HAAPARANTASOLIN M; SOLIN O; KUOPPAMAKI M; SYVALAHTI E; HIETALA J
      STRIATAL PRESYNAPTIC DOPAMINE FUNCTION IN TYPE-1 ALCOHOLICS MEASURED WITH POSITRON-EMISSION-TOMOGRAPHY

      Molecular psychiatry
    20. KAJANDER J; VILKMAN H; SYVALAHTI E; NAGREN K; HIETALA J
      EFFECTS OF REPEATED FLUOXETINE TREATMENT ON STRIATAL D-2 DOPAMINE BINDING IN HUMANS, MEASURED WITH POSITRON-EMISSION-TOMOGRAPHY

      Nordic journal of psychiatry
    21. Saarijarvi, S; Taiminen, T; Syvalahti, E; Niemi, H; Ahola, V; Lehto, H; Salokangas, RKR
      Relatives' participation in a clinical drug trial of schizophrenic outpatients improves their psychologic well-being

      NORDIC JOURNAL OF PSYCHIATRY
    22. TAIMINEN TJ; SALOKANGAS RKR; SAARIJARVI S; NIEMI H; LEHTO H; AHOLA V; SYVALAHTI E
      SMOKING AND COGNITIVE DEFICITS IN SCHIZOPHRENIA - A PILOT-STUDY

      Addictive behaviors
    23. POHJALAINEN T; RINNE JO; NAGREN K; SYVALAHTI E; HIETALA J
      SEX-DIFFERENCES IN THE STRIATAL DOPAMINE D-2 RECEPTOR-BINDING CHARACTERISTICS IN-VIVO

      The American journal of psychiatry
    24. PALVIMAKI EP; MAJASUO H; KUOPPAMAKI M; MANNISTO PT; SYVALAHTI E; HIETALA J
      DERAMCICLANE, A PUTATIVE ANXIOLYTIC DRUG, IS A SEROTONIN 5-HT2C RECEPTOR INVERSE AGONIST BUT FAILS TO INDUCE 5-HT2C RECEPTOR DOWN-REGULATION

      Psychopharmacology
    25. SALOKANGAS RKR; SAARIJARVI S; TAIMINEN T; LEHTO H; NIEMI H; AHOLA V; SYVALAHTI E
      EFFECT OF SMOKING ON NEUROLEPTICS IN SCHIZOPHRENIA

      Schizophrenia research
    26. GACSALYI I; SCHMIDT E; GYERTYAN I; VASAR E; LANG A; HAAPALINNA A; FEKETE M; HIETALA J; SYVALAHTI E; TUOMAINEN P; MANNISTO PT
      RECEPTOR-BINDING PROFILE AND ANXIOLYTIC-TYPE ACTIVITY OF DERAMCICLANE(EGIS-3886) IN ANIMAL-MODELS

      Drug development research
    27. TAIMINEN TJ; SYVALAHTI E; SAARIJARVI S; NIEMI H; LEHTO H; AHOLA V; SALOKANGAS RKR
      CITALOPRAM AS AN ADJUVANT IN SCHIZOPHRENIA - FURTHER EVIDENCE FOR A SEROTONERGIC DIMENSION IN SCHIZOPHRENIA

      International clinical psychopharmacology
    28. TAIMINEN T; SYVALAHTI E; SAARIJARVI S; NIEMI H; LEHTO H; AHOLA V; SALOKANGAS RKR
      IS POSITIVE PLACEBO-RESPONSE IN CHRONIC-SCHIZOPHRENIA INVESTIGATOR-DEPENDENT

      The Journal of nervous and mental disease
    29. POHJALAINEN T; CRAVCHIK A; GEJMAN PV; RINNE J; NAGREN K; SYVALAHTI E; HIETALA J
      ANTAGONIST BINDING CHARACTERISTICS OF THE SER(311)-]CYS VARIANT OF HUMAN DOPAMINE D-2 RECEPTOR IN-VIVO AND IN-VITRO

      Biochemical and biophysical research communications
    30. HIETALA J; KUOPPAMAKI M; NAGREN K; LEHIKOINEN P; SYVALAHTI E
      EFFECTS OF LORAZEPAM ADMINISTRATION ON STRIATAL DOPAMINE D-2 RECEPTOR-BINDING CHARACTERISTICS IN MAN - A POSITRON EMISSION TOMOGRAPHY STUDY

      Psychopharmacology
    31. LAAKSO A; PALVIMAKI EP; KUOPPAMAKI M; SYVALAHTI E; HIETALA J
      CHRONIC CITALOPRAM AND FLUOXETINE TREATMENTS UP-REGULATE 5-HT2C RECEPTORS IN THE RAT CHOROID-PLEXUS

      Neuropsychopharmacology
    32. LEHTINEN V; AALTONEN J; KOFFERT T; RAKKOLAINEN V; SYVALAHTI E; VUORIO K
      INTEGRATED TREATMENT MODEL FOR FIRST-CONTACT PATIENTS WITH A SCHIZOPHRENIA-TYPE PSYCHOSIS - THE FINNISH API PROJECT

      Nordic journal of psychiatry
    33. HIETALA J; SYVALAHTI E
      DOPAMINE IN SCHIZOPHRENIA

      Annals of medicine
    34. TAIMINEN T; SYVALAHTI E; SAARIJARVI S; NIEMI H; LEHTO H; AHOLA V; SALOKANGAS RKR
      PREDICTION OF POSITIVE PLACEBO-RESPONSE AMONG CHRONIC-SCHIZOPHRENIC OUTPATIENTS

      The Journal of nervous and mental disease
    35. WONG G; KUOPPAMAKI M; HIETALA J; LUDDENS H; SYVALAHTI E; KORPI ER
      EFFECTS OF CLOZAPINE METABOLITES AND CHRONIC CLOZAPINE TREATMENT ON RAT-BRAIN GABA(A) RECEPTORS

      European journal of pharmacology
    36. SALOKANGAS RKR; SAARIJARVI S; TAIMINEN T; KALLIONIEMI H; LEHTO H; NIEMI H; TUOMINEN J; AHOLA V; SYVALAHTI E
      CITALOPRAM AS AN ADJUVANT IN CHRONIC-SCHIZOPHRENIA - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY

      Acta psychiatrica Scandinavica
    37. TIIHONEN J; KUOPPAMAKI M; NAGREN K; BERGMAN J; ERONEN E; SYVALAHTI E; HIETALA J
      SEROTONERGIC MODULATION OF STRIATAL D-2 DOPAMINE-RECEPTOR BINDING IN HUMANS MEASURED WITH POSITRON EMISSION TOMOGRAPHY

      Psychopharmacology
    38. PALVIMAKI EP; ROTH BL; MAJASUO H; LAAKSO A; KUOPPAMAKI M; SYVALAHTI E; HIETALA J
      INTERACTIONS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS WITH THE SEROTONIN 5-HT2C RECEPTOR

      Psychopharmacology
    39. KUOPPAMAKI M; PALVIMAKI EP; HIETALA J; SYVALAHTI E
      DIFFERENTIAL REGULATION OF RAT 5-HT2A AND 5-HT2C RECEPTORS AFTER CHRONIC TREATMENT WITH CLOZAPINE, CHLORPROMAZINE AND 3 PUTATIVE ATYPICAL ANTIPSYCHOTIC-DRUGS

      Neuropsychopharmacology
    40. HIETALA J; SYVALAHTI E; VUORIO K; RAKKOLAINEN V; BERGMAN J; HAAPARANTA M; SOLIN O; KUOPPAMAKI M; KIRVELA O; RUOTSALAINEN U; SALOKANGAS RKR
      PRESYNAPTIC DOPAMINE FUNCTION IN STRIATUM OF NEUROLEPTIC-NAIVE SCHIZOPHRENIC-PATIENTS

      Lancet
    41. PALVE H; KIRVELA O; OLIN H; SYVALAHTI E; KANTO J
      MAXIMUM RECOMMENDED DOSES OF LIGNOCAINE ARE NOT TOXIC

      British Journal of Anaesthesia
    42. LONNQVIST J; SIHVO S; SYVALAHTI E; SINTONEN H; KIVIRUUSU O; PITKANEN H
      MOCLOBEMIDE AND FLUOXETINE IN THE PREVENTION OF RELAPSES FOLLOWING ACUTE TREATMENT OF DEPRESSION

      Acta psychiatrica Scandinavica
    43. KUOPPAMAKI M; SEPPALA T; SYVALAHTI E; HIETALA J
      REGULATION OF SEROTONIN 5-HT2C RECEPTORS IN THE RAT CHOROID-PLEXUS AFTER ACUTE CLOZAPINE TREATMENT

      European journal of pharmacology. Molecular pharmacology section
    44. LONNQVIST J; SIHVO S; SYVALAHTI E; KIVIRUUSU O
      MOCLOBEMIDE AND FLUOXETINE IN ATYPICAL DEPRESSION - A DOUBLE-BLIND TRIAL

      Journal of affective disorders
    45. KUOPPAMAKI M; PALVIMAKI EP; SYVALAHTI E; HIETALA J
      5-HT1C RECEPTOR-MEDIATED PHOSPHOINOSITIDE HYDROLYSIS IN THE RAT CHOROID-PLEXUS AFTER CHRONIC TREATMENT WITH CLOZAPINE

      European journal of pharmacology
    46. HIETALA J; SYVALAHTI E; VUORIO K; NAGREN K; LEHIKOINEN P; RUOTSALAINEN U; RAKKOLAINEN V; LEHTINEN V; WEGELIUS U
      STRIATAL D-2, DOPAMINE-RECEPTOR CHARACTERISTICS IN NEUROLEPTIC-NAIVE SCHIZOPHRENIC-PATIENTS STUDIED WITH POSITRON EMISSION TOMOGRAPHY

      Archives of general psychiatry
    47. LONNQVIST J; SINTONEN H; SYVALAHTI E; APPELBERG B; KOSKINEN T; MANNIKKO T; MEHTONEN OP; NAARALA M; SIHVO S; AUVINEN J; PITKANEN H
      ANTIDEPRESSANT EFFICACY AND QUALITY-OF-LIFE IN DEPRESSION - A DOUBLE-BLIND-STUDY WITH MOCLOBEMIDE AND FLUOXETINE

      Acta psychiatrica Scandinavica
    48. HIETALA J; WEST C; SYVALAHTI E; NAGREN K; LEHIKOINEN P; SONNINEN P; RUOTSALAINEN U
      STRIATAL D-2 DOPAMINE-RECEPTOR BINDING CHARACTERISTICS IN-VIVO IN PATIENTS WITH ALCOHOL DEPENDENCE

      Psychopharmacology
    49. PALVIMAKI EP; LAAKSO A; KUOPPAMAKI M; SYVALAHTI E; HIETALA J
      UP-REGULATION OF BETA(1)-ADRENERGIC RECEPTORS IN RAT-BRAIN AFTER CHRONIC CITALOPRAM AND FLUOXETINE TREATMENTS

      Psychopharmacology
    50. KUOPPAMAKI M; SYVALAHTI E; HIETALA J
      CLOZAPINE AND N-DESMETHYLCLOZAPINE ARE POTENT 5-HT(1C) RECEPTOR ANTAGONISTS

      European journal of pharmacology. Molecular pharmacology section


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 03:47:01